MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer ...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four ...
MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present late-breaking ...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in ...
Shares of Exact Sciences (NASDAQ:EXAS) gained on Wednesday after the maker of the Cologuard stool-based cancer test announced plans to release data from a blood-based cancer test on Sept. 16. At Baird ...
Circulating tumor DNA (ctDNA) analysis and advanced tumor profiling in GI cancers highlight opportunities for recurrence monitoring and targeted therapy selection Modeling analyses and real-world ...
MADISON, Wis., Oct. 20, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the ...
Exact Sciences has put forward positive data on its approach to screening for esophageal tumors and the disease’s precancerous conditions with a method that may allow patients to skip a sedated ...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results